<DOC>
	<DOCNO>NCT03101839</DOCNO>
	<brief_summary>A Phase I , open-label , multicentre , dose-escalation study investigate safety , pharmacokinetics maximum tolerate dose ( MTD ) AZD4785 patient advance solid tumour KRAS may important driver tumour survival . Part A : Dose escalation patient solid tumour evaluate safety , pharmacokinetics dose Part B : Expansion cohort select dose patient non small cell lung cancer evaluate pharmacodynamics clinical response</brief_summary>
	<brief_title>Phase I Dose-Escalation Study AZD4785 Patients With Advanced Solid Tumours</brief_title>
	<detailed_description>This First-Time-in-Human ( FTIH ) , Phase 1 study determine MTD , recommend Phase 2 dose ( RP2D ) , safety , tolerability , pharmacodynamics , pharmacokinetics AZD4785 . The study conduct two part : dose-escalation part ( Part A ) expansion part ( Part B ) . Part B include three patient group . Patients must KRAS mutation ( KRASm+ ) identify tumour tissue sample order enter study . AZD4785 give IV infusion 1 hour , initially 3 load dos first week weekly thereafter . The loading dose give Days 1 , 3 , 5 first week weekly thereafter Days 8 , 15 , 22 28 Day cycle . In subsequent cycle AZD4785 administer Days 1 , 8 , 15 , 22 disease progression , intolerable toxicity , discontinuation criterion meet .</detailed_description>
	<criteria>Inclusion Criteria Part A : Adult patient solid tumour know harbour KRAS mutation standard therapy available . Part B : Adult patient locally advance metastatic nonsmall cell lung cancer know harbour KRAS mutation standard therapy available . 1 . Signed write informed consent 2 . ≥ 18 year old 3 . Adequate organ system function indicate : 1 . Absolute neutrophil count ( ANC ) ≥ 1.5 x 10 ( exp9 ) /L 2 . Platelets ≥ 100 x 10 ( exp9 ) /L 3 . Haemoglobin ≥ 9g/dL 4 . Activated partial thromboplastin time ( aPTT ) ≤ 1.5 time upper limit normal ( ULN ) 5 . Total bilirubin ≤ 1.5 mg/dL 6 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3.0 time ULN liver involvement ≤ 5 time ULN liver involvement . 7 . Creatinine ≤ 1.5 time ULN creatinine clearance ≥ 60 mL/min calculate CockcroftGault method , 24 hour measure urine creatinine clearance ≥ 60 mL/min . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 5 . Life expectancy ≥ 12 week 6 . Willing use appropriate method contraception 1 . Patients receive chemotherapy , radiotherapy , hormonal therapy , immunotherapy investigational drug within 21 day 5 half life ( whichever short ) enrolment . 2 . With exception alopecia , unresolved toxicity prior therapy great National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) Grade 1 time enrolment . 3 . Unresolved immunotherapyrelated hepatotoxicity previous therapy . 4 . Major surgery ( exclude placement vascular access ) ≤ 21 day begin enrolment minor surgical procedure ≤ 7 day . No wait require follow implantable port catheter placement . 5 . Patients receive fulldose anticoagulation therapy . 6 . Has active prior document autoimmune disease within past 2 year exception vitiligo , Grave 's disease , and/or psoriasis require systemic treatment . 7 . Has history atypical Haemolytic Uremic Syndrome . 8 . Patients leptomeningeal metastasis . 9 . Previously untreated brain metastasis . Patients receive radiation surgery brain metastasis eligible therapy complete least 3 week prior enrolment evidence central nervous system disease progression mild neurologic symptom , requirement chronic corticosteroid therapy . 10 . Evidence severe uncontrolled systemic disease , include uncontrolled hypertension , active bleeding diatheses , active infection include hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) . 11 . Any following cardiac criterion : 1 . Congestive heart failure ( CHF ) per New York Heart Association ( NYHA ) classification &gt; Class II . 2 . Cardiac ventricular arrhythmia require antiarrhythmic therapy . 3 . Unstable angina newonset angina . 4 . QT interval ( QTcF ) &gt; 470 m screen electrocardiogram ( ECG ) Fridericia 's formula . 12 . History hypersensitivity active inactive excipients AZD4785 drug similar chemical structure class AZD4785 . 13 . Judgment Investigator patient participate study patient unlikely comply study procedure , restriction requirement . 14 . Psychological , familial , sociological , geographical condition permit compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>